Update on Andexanet Alfa for Reversal of FXa Inhibitors: Annexa-I Trial Webinar
59:31
Anticoagulants in Older Adults
1:00:08
Women’s Health Considerations in Thrombosis Webinar
8:07
Current opinions on andexanet alfa
56:26
Navigating the 2024 PAD Guidelines
7:53
Secondary analyses from ANNEXA-I: identifying predictors of hematoma expansion and thrombotic events
32:51
Reversing oral anticoagulants with a focus on Andexanet Alfa
58:06
Ask the Experts
20:59